|
18 Jan 2022 |
Almirall and IRB Barcelona announce a research collaboration to discover novel molecular glue therapeutics for severe skin diseases
|
|
13 Jan 2022 |
ITM and Helmholtz Munich Sign Cooperation Agreement for the Clinical Development of Radiopharmaceutical Therapy to Treat Glioblastoma Multiforme
|
|
13 Jan 2022 |
AstraZeneca and Scorpion Therapeutics enter agreement to discover, develop and commercialise novel cancer treatments against ‘undruggable’ targets
|
|
12 Jan 2022 |
Neogene Therapeutics Announces Exclusive License with the National Cancer Institute for a Portfolio of T Cell Receptors (TCR) Targeting KRAS and TP53 Mutations for the Treatment of Cancer
|
|
12 Jan 2022 |
Dren Bio Announces Research Collaboration and License Agreement with Pfizer to Discover and Advance Multiple Therapeutic Antibodies Using its Targeted Myeloid Engager and Phagocytosis Platform for the Treatment of Cancer
|
|
12 Jan 2022 |
Fusion Pharmaceuticals Announces Research Collaboration with Pepscan to Develop Peptide-Based Radiopharmaceuticals
|
|
12 Jan 2022 |
Fusion Pharmaceuticals Announces Research Collaboration with 48Hour Discovery to Develop Peptide-Based Radiopharmaceuticals
|
|
12 Jan 2022 |
NeoCura and PhoreMost Announce Research Collaboration to Explore Novel Cancer Therapeutics
|
|
12 Jan 2022 |
ABL Bio Enters Global Collaboration and License Agreement with SANOFI to Advance ABL301 for the Treatment of Parkinson's Disease
|
|
10 Jan 2022 |
Cullinan Oncology Forms Strategic Collaboration Agreement with Mount Sinai to Advance Oral HPK1 Protein Degrader for Cancer Treatment
|
|
10 Jan 2022 |
Moderna and Carisma Establish Collaboration to Develop in vivo Engineered Chimeric Antigen Receptor Monocytes (CAR-M) for Oncology
|
|
10 Jan 2022 |
TrialSpark licenses sprifermin, an investigational first-in-class disease modifying treatment for osteoarthritis, from Merck KGaA, Darmstadt, Germany and announces formation of High Line Bio
|
|
10 Jan 2022 |
Pfizer and Beam Enter Exclusive Multi-Target Research Collaboration to Advance Novel In Vivo Base Editing Programs for a Range of Rare Diseases
|
|
10 Jan 2022 |
Pfizer Enters into Agreement with Acuitas Therapeutics for Lipid Nanoparticle Delivery System for Use in mRNA Vaccines and Therapeutics
|
|
10 Jan 2022 |
Takeda to Acquire Adaptate Biotherapeutics to Develop Novel Gamma Delta (γδ) T Cell Engager Therapies Targeting Solid Tumors
|
|
10 Jan 2022 |
Bayer and Mammoth Biosciences to collaborate on novel gene editing technology
|
|
08 Jan 2022 |
Absci Announces Research Collaboration with Merck
|
|
07 Jan 2022 |
Ambagon Therapeutics Launches With $85 Million Series A to Advance Pioneering Molecular Glue Platform and Progress Pipeline
|
|
07 Jan 2022 |
Exscientia and Sanofi Establish Strategic Research Collaboration to Develop AI-driven Pipeline of Precision-Engineered Medicines
|
|
07 Jan 2022 |
Alnylam Announces Collaboration with Novartis to Explore Targeted Therapy to Restore Liver Function
|
|
06 Jan 2022 |
Amgen and Generate Biomedicines Announce Multi-Target, Multi-Modality Research Collaboration Agreement
|
|
06 Jan 2022 |
Lilly and Entos Pharmaceuticals Enter into Research and Collaboration Agreement to Support the Development of Innovative Therapies in Multiple Neurologic Indications
|
|
06 Jan 2022 |
POLARISqb and PhoreMost announce a multi-target collaboration to investigate next-generation cancer therapies
|
|
06 Jan 2022 |
Eisai Enters Into Exclusive Licensing Agreement with Roivant Concerning Investigational Anticancer Agent H3B-8800, a Splicing Modulator
|
|
06 Jan 2022 |
Intellia Therapeutics and Kyverna Therapeutics Announce Collaboration to Develop Next-Generation Allogeneic T-Cell Therapy for Autoimmune Diseases
|
